Основная статистика
| LEI | 549300TLN1G9WX00KA57 |
| CIK | 1196298 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Nephros, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction (Commission (IRS Employer of incorporati |
|
| August 11, 2025 |
Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Strong Second Quarter Financial Results Second-Quarter Net Revenue of $4.4 million; Robust Growth Drives 36% Increase in Net Revenue with Third Consecutive Quarter of Profitability SOUTH ORANGE, NJ, August 7, 2025 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPHROS, |
|
| June 16, 2025 |
UNITES STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2025 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPHROS, |
|
| May 15, 2025 |
Amendment to Letter Agreement, dated February 26, 2025, between the Company and Judy Krandel. * † Exhibit 10.1 |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 8, 2025 |
Exhibit 99.1 Nephros Announces Financial Results for Quarter Ended March 31, 2025 First-Quarter Net Revenue of $4.9 million; Robust Growth Drives 38% Increase in Net Revenue SOUTH ORANGE, NJ, May 8, 2025 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the first quarter end |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 23, 2025 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 1, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2025 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| April 1, 2025 |
Nephros, Inc. 2024 Corporate Presentation. Exhibit 99.1 |
|
| March 24, 2025 |
Form of Stock Option Agreement under 2024 Equity Incentive Plan. *† Exhibit 10.7 NEPHROS, INC. 2024 EQUITY INCENTIVE PLAN NOTICE OF STOCK OPTION GRANT Nephros, Inc. (the “Company”), pursuant to its 2024 Equity Incentive Plan (the “Plan”), hereby grants to the Participant identified below an option to purchase the number of shares of the Company’s Common Stock set forth below (the “Option”). This Option is subject to all of the terms and conditions as set forth in |
|
| March 24, 2025 |
Form of Restricted Stock Grant Notice under 2024 Equity Incentive Plan. *† Exhibit 10.8 NEPHROS, INC. 2024 EQUITY INCENTIVE PLAN RESTRICTED STOCK GRANT NOTICE Nephros, Inc. (the “Company”), pursuant to its 2024 Equity Incentive Plan (the “Plan”), hereby awards to Participant identified below a Restricted Stock Award for the number of shares of the Company’s Common Stock (the “Restricted Stock”) set forth below (the “Award”). The Award is subject to all of the terms and c |
|
| March 24, 2025 |
Nephros, Inc. Insider Trading Policy. * Exhibit 19.1 POLICY STATEMENT ON INSIDE INFORMATION AND SECURITIES TRADING BY NEPHROS, INC. As of February 26, 2020 SUMMARY This Policy Statement on Inside Information and Securities Trading (the “Policy Statement”) provides guidelines for directors, officers, employees, or other types of representatives of Nephros, Inc. and its subsidiaries (collectively, the “Company”) who may have access to mat |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32288 NEPHROS, INC. |
|
| March 6, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2025 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 6, 2025 |
Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Fourth Quarter and Fiscal Year 2024 Financial Results Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.9 Million SOUTH ORANGE, NJ, March 6, 2025 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medi |
|
| March 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation) 001-32288 (Commission File Number) 13-39 |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPH |
|
| November 13, 2024 |
Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Financial Results for Quarter Ended September 30, 2024 Third-Quarter Net Revenue of $3.5 Million; Operational Improvements Result In First Profitable Quarter SOUTH ORANGE, NJ, November 7, 2024 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2024 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 26, 2024 |
Nephros, Inc. 2024 Corporate Presentation. Exhibit 99.1 |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPHROS, |
|
| June 17, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Nephros, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rate (1) Amount Registered (2) Proposed Maximum Offering Price Per Share (3) Maximum Aggregate Offering Price Fee Rate Amount of Registration fee Equity Common Stock issuable un |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of 1933 NEPHROS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 13-3971809 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 380 Lackawanna Place South Orange, New Jersey 07079 (Address of Princip |
|
| May 24, 2024 |
UNITES STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 24, 2024 |
Nephros, Inc. 2024 Equity Incentive Plan. Exhibit 10.1 Nephros, Inc. 2024 Equity Incentive Plan Adopted by the Board of Directors: April 12, 2024 Approved by the Stockholders: May 23, 2024 1. General. (a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan’s Available Reserve |
|
| May 21, 2024 |
NEPHROS, INC. 380 Lackawanna Place South Orange, New Jersey 07079 (201) 343-5202 NEPHROS, INC. 380 Lackawanna Place South Orange, New Jersey 07079 (201) 343-5202 May 21, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Mr. Robert Augustin Re: Nephros, Inc. Registration Statement on Form S-3 File Number: 333-279328 Dear Mr. Augustin: In accordance with Rule 461 under the Securities Act of 1933, |
|
| May 10, 2024 |
Exhibit 4.10 NEPHROS, INC. and , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1. DEFINITIONS. 1 1.2. OTHER DEFINITIONS. 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT. 4 1.4. RULES OF CONSTRUCTION. 5 ARTICLE 2 THE SECURITIES 5 2.1. ISSUABLE IN SERIES. 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES. 5 2.3. EXECUT |
|
| May 10, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Nephros, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (1) Maximum Aggregate Offering Price (1) Fee Rate Amount of Registration F |
|
| May 10, 2024 |
As filed with the Securities and Exchange Commission on May 10, 2024 As filed with the Securities and Exchange Commission on May 10, 2024 Registration No. |
|
| May 9, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation) 001-32288 (Commission File Number) 13-3971809 |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPHROS, |
|
| May 9, 2024 |
Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Financial Results for Quarter Ended March 31, 2024 First-Quarter Net Revenue of $3.5 Million; Technology advancements and microplastics capabilities on the horizon SOUTH ORANGE, NJ, May 09, 2024 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtratio |
|
| May 1, 2024 |
Nephros, Inc. 2024 Corporate Presentation. Exhibit 99.1 |
|
| May 1, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2024 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation) 001-32288 (Commission File Number) 13-3971809 |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 15, 2024 |
Letter Agreement, dated July 28, 2023, between the Nephros, Inc. and Judy Krandel. * † Exhibit 10.31 July 28, 2023 Judith Krandel Dear Judy, I am very pleased to offer you the position of Chief Financial Officer (CFO) at Nephros (“the Company”). Initially, the position is targeted at an expected time commitment of 50% and the compensation is structured at the same level. This percentage – of both time and pay – may be increased or decreased from time to time by mutual agreement, in |
|
| March 15, 2024 |
List of Subsidiaries of Nephros, Inc. * Exhibit 21.1 Subsidiaries of Nephros, Inc. Name Jurisdiction Percentage Equity Biocon 1, LLC Nevada 100% Aether Water Systems, LLC Nevada 100% |
|
| March 15, 2024 |
Exhibit 10.34 Pursuant to Item 601 of Regulation S-K, certain information in this Exhibit 10.34 has been redacted. Information that was redacted has been noted in this document with a placeholder identified by the mark “[*****].” The registrant believes the redacted information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. If requested by the Com |
|
| March 15, 2024 |
Exhibit 10.32 NEPHROS, INC. INDUCEMENT STOCK OPTION AGREEMENT THIS INDUCEMENT STOCK OPTION AGREEMENT (this “Agreement”), made effective as of this 1st day of November, 2023, by and between Nephros, Inc., a Delaware corporation (the “Company”), and Judy Krandel (“Participant”). W I T N E S S E T H: WHEREAS, the Company maintains the Nephros, Inc. 2015 Equity Incentive Plan (as it may be amended and |
|
| March 15, 2024 |
Nephros, Inc. Policy for Recoupment of Erroneously Awarded Compensation. * Exhibit 97.1 NEPHROS, INC. Policy for the Recoupment of Erroneously Awarded Compensation Description Nephros, Inc., a Delaware corporation (the “Company”), has adopted this Policy for the Recoupment of Erroneously Awarded Compensation (the “Policy”), pursuant to the requirements of Nasdaq Listing Rule 5608 and Securities Exchange Act Rule 10D-1. The Policy sets forth the circumstances under which |
|
| March 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32288 NEPHROS, INC. |
|
| March 7, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 7, 2024 |
Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call:201 343 5202 nephros.com Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results Full-Year Net Revenue of $14.2 Million and Fourth-Quarter Net Revenue of $3.3 Million SOUTH ORANGE, NJ, March 7, 2024 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medic |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPH |
|
| November 8, 2023 |
Exhibit 10.1 August 9, 2023 Andrew Astor [Address] [Address] Dear Andy, Reference is made to that certain Employment Agreement between you and Nephros, Inc. (the “Company”) dated August 23, 2020 (the “Employment Agreement”). This letter agreement is intended to serve as an amendment to the Employment Agreement by setting forth modified terms of your employment with the Company following your retir |
|
| November 6, 2023 |
Nephros Hires Judy Krandel as Chief Financial Officer Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Hires Judy Krandel as Chief Financial Officer SOUTH ORANGE, NJ, November 1, 2023 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, announced the appointment of Judy Krandel as Chief Financial Officer (CFO |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 9, 2023 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), is entered into as of May 4, 2023, by and between Nephros, Inc., a Delaware corporation having its executive offices and principal place of business at 380 Lackawanna Place, South Orange, New Jersey 07079 (the “Company”), and Robert Banks (“Executive”). RECITALS WHEREAS, the Company desires to employ Executive as its P |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPHROS, |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 9, 2023 |
Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Results for Quarter Ended June 30, 2023 Second-Quarter Net Revenue of $3.5 Million, a 24% Increase Over 2022; Year-to-Date Revenue Increases 45%; Maintains Positive Cash Flow Results SOUTH ORANGE, NJ, August 9, 2023 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology compan |
|
| June 1, 2023 |
Submission of Matters to a Vote of Security Holders UNITES STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 1, 2023 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 11, 2023 |
Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces CEO Retirement and Succession Plan Robert Banks to Be Named President and Chief Executive Officer; Andy Astor to Remain as Advisor and Interim Chief Financial Officer SOUTH ORANGE, NJ, May 8, 2023 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtrat |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPHROS, |
|
| April 28, 2023 |
DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| April 4, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2023 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 4, 2023 |
Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Preliminary Results for First Quarter 2023 Net Revenue of $3.7 Million, a 69% Year-Over-Year Increase SOUTH ORANGE, NJ, April 4, 2023 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today anno |
|
| March 23, 2023 |
List of Subsidiaries of Nephros, Inc. * Exhibit 21.1 Subsidiaries of Nephros, Inc. Name Jurisdiction Percentage Equity Biocon 1, LLC Nevada 100% Aether Water Systems, LLC Nevada 100% Specialty Renal Products, Inc. Delaware 62.5% |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32288 NEPHROS, INC. |
|
| March 8, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 8, 2023 |
Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Fourth Quarter and Fiscal Year 2022 Financial Results Full-Year Net Revenue of $10 Million and Fourth Quarter Net Revenue of $2.6 Million SOUTH ORANGE, NJ, March 8, 2023 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medica |
|
| February 3, 2023 |
PDFS / PDF Solutions, Inc. / Cowen Prime Advisors LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PDF Solutions Inc (Name of Issuer) Common Stock (Title of Class of Securities) 693282105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 30, 2023 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 3, 2023 |
HTGM / HTG Molecular Diagnostics Inc / Cowen Prime Advisors LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40434H104 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 3, 2023 |
NEPH / Nephros, Inc. / Cowen Prime Advisors LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nephros, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 640671400 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| January 11, 2023 |
Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Preliminary Results for Fourth Quarter and Fiscal Year 2022 Fourth Quarter Net Revenue of $2.6 Million; Full-Year Net Revenue of $10.0 Million; Active Customer Sites Continue to Climb SOUTH ORANGE, NJ, January 11, 2023 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology com |
|
| January 11, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 21, 2022 |
Exhibit 2.1 Pursuant to Item 601 of Regulation S-K, certain information in this Exhibit 2.1 has been redacted. Information that was redacted has been noted in this document with a placeholder identified by the mark ?[*****].? The Registrant believes the redacted information is both (i) not material and (ii) the type that the Registrant treats as private or confidential. If requested by the Commiss |
|
| November 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2022 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 21, 2022 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.1 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS On November 15, 2022, Nephros, Inc. (?the Company?) consummated the transactions contemplated by the Agreement for Purchase and Sale of Assets, dated October 4, 2022 (the ?Purchase Agreement?), between the Company and BWSI, LLC (the ?Purchaser?), pursuant to which the Company agreed to sell substantially all of the assets |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-32288 NOTIFICATION OF LATE FILING CUSIP NUMBER 640671103 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tr |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPH |
|
| November 2, 2022 |
Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Results for Quarter Ended September 30, 2022 Third-Quarter Net Revenue of $2.4 Million; Active Customer Sites Increase 18% YoY to a New Record Level SOUTH ORANGE, NJ, November 2, 2022 ? Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions |
|
| November 2, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2022 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 11, 2022 |
Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Agreement to Sell Pathogen Detection Systems Business and Preliminary Results for Quarter Ended September 30, 2022 Sale Reduces Cash Burn, Includes Seven-Year Earn-Out Provision; Third Quarter Revenue Expected to be Approximately $2.5 Million; Active Customer Sites Increase 18% Yo |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2022 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 8, 2022 |
Nephros Appoints Joe Harris to Its Board of Directors Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Appoints Joe Harris to Its Board of Directors SOUTH ORANGE, NJ, September 8, 2022 ? Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Joe Harris to |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2022 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation) 001-32288 (Commission File Number) 13-39 |
|
| August 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 17, 2022 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPHROS, |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 10, 2022 |
Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Results for Quarter Ended June 30, 2022 Second Quarter Net Revenue of $2.9 Million, a 27% Year-Over-Year Increase; Active Customer Sites Climb 21% to New Record SOUTH ORANGE, NJ, August 10, 2022 ? Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtratio |
|
| July 6, 2022 |
Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Preliminary Results for Quarter Ended June 30, 2022 and Projects Positive Net Cash Flow in 12 Months Second Quarter Revenue of $2.9 Million, Year-Over-Year Increase of 27%; Number of Active Customer Sites Climbs 21% Year-Over-Year SOUTH ORANGE, NJ, July 6, 2022 ? Nephros, Inc. (Na |
|
| July 6, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 6, 2022 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 20, 2022 |
Submission of Matters to a Vote of Security Holders UNITES STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2022 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 17, 2022 |
Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Receives FDA 510(k) Clearance for HDF Assist Module The First and Only FDA-Cleared Device Available in the United States to Provide Hemodiafiltration Therapy to Dialysis Patients SOUTH ORANGE, NJ, May 17, 2022 ? Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filt |
|
| May 17, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPHROS, |
|
| May 5, 2022 |
Exhibit 10.3 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SPECIALTY RENAL PRODUCTS, INC. It is hereby certified that: FIRST: Specialty Renal Products, Inc. (the ?Corporation?) is a corporation formed under the laws of the State of Delaware, and its Certificate of Incorporation was initially filed in the office of the Secretary of State on July 2, 2018, and Amend |
|
| May 5, 2022 |
Exhibit 10.1 FIRST AMENDMENT TO LOAN AGREEMENT This First Amendment to Loan Agreement (this ?Amendment?) is entered into as of January 19, 2022, by and among Specialty Renal Products, Inc., a Delaware corporation (?Borrower?), and Nephros, Inc., a Delaware corporation ( ?Lender?). WHEREAS, Borrower and Lender are parties to that certain Loan Agreement dated October 7, 2020 (the ?Loan Agreement?), |
|
| May 5, 2022 |
Exhibit 10.2 sPECIALTY RENAL PRODUCTS, INC. FIRST AMENDMENT TO SERIES A PREFERRED STOCK PURCHASE AGREEMENT This Amendment (the ?Amendment?) is entered into as of February 1, 2022, by and among Specialty Renal Products, Inc., a Delaware corporation (the ?Company?), and the Purchasers identified on the signature pages to this Amendment. WHEREAS, the Company and the undersigned Purchasers are parties |
|
| May 4, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2022 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 4, 2022 |
Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Results for Quarter Ended March 31, 2022 First Quarter Net Revenue of $2.2 Million; Active Customer Sites Climb 17% to New Record SOUTH ORANGE, NJ, May 4, 2022 ? Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions |
|
| April 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| March 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32288 NEPHROS, INC. |
|
| March 3, 2022 |
List of Subsidiaries of Nephros, Inc. * Exhibit 21.1 Subsidiaries of Nephros, Inc. Name Jurisdiction Percentage Equity Nephros International Limited Ireland 100% Biocon 1, LLC Nevada 100% Aether Water Systems, LLC Nevada 100% Specialty Renal Products, Inc. Delaware 62.5% |
|
| February 23, 2022 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Announces Fourth Quarter and Fiscal Year 2021 Financial Results Reports Full-Year Net Revenue of $10.4 Million, a 22% Year-Over-Year Increase and Fourth Quarter Net Revenue of $2.8 Million, an 18% Year-Over-Year Increase; Reaffirms Fiscal Year 2022 Guidance of $13.0 Mil |
|
| February 23, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2022 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 10, 2022 |
NEPH / Nephros, Inc. / Cowen Prime Services LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nephros, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 640671400 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 10, 2022 |
RSSS / Research Solutions Inc / Cowen Prime Services LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Research Solutions Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 761025105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 10, 2022 |
NEPH / Nephros, Inc. / Cowen Prime Services LLC Passive Investment SC 13G 1 s22-22221bcowen13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Iteris, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 46564t107 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 10, 2022 |
HTGM / HTG Molecular Diagnostics Inc / Cowen Prime Services LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* HTG Molecular Diagnostics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 40434H104 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi |
|
| February 10, 2022 |
PDFS / PDF Solutions, Inc. / Cowen Prime Services LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PDF Solutions Inc (Name of Issuer) Common Stock (Title of Class of Securities) 693282105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| February 9, 2022 |
NEPH / Nephros, Inc. / Cowen Prime Advisors LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nephros, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 640671400 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| February 8, 2022 |
NEPH / Nephros, Inc. / Samjo Capital LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 13, 2022 |
Exhibit 99.1 Nephros Announces Preliminary Results for Fourth Quarter and Fiscal Year 2021 and Revenue Guidance for 2022 Anticipates Record Full-Year Net Revenue of $10.4 Million, a 21% Year-Over-Year Increase and Fourth Quarter Revenue of $2.8 Million, an 18% Year-Over-Year Increase; Provides 2022 Guidance of $13.0 Million to $13.5 Million in Annual Revenue SOUTH ORANGE, NJ, January 11, 2022 ? Ne |
|
| January 13, 2022 |
Nephros Issues 2022 Shareholder Letter Exhibit 99.2 Nephros, Inc. 380 Lackawanna Place South Orange NJ 07079 Call: 201 343 5202 nephros.com Nephros Issues 2022 Shareholder Letter SOUTH ORANGE, NJ, January 13, 2022 ? Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today issued a 2022 letter to shareholders. Dear Shareholder, We |
|
| January 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Num |
|
| December 3, 2021 |
Letter from Moody, Famiglietti and Andronico, LLP dated December 2, 2021. Exhibit 16.1 December 2, 2021 Securities and Exchange Commission 100 F Street, NE Washington, DC 20549 Dear Ladies and Gentlemen: We are the former independent registered public accounting firm for Nephros, Inc. (the ?Company?). We have read the Company?s disclosure set forth in Item 4.01 ?Changes in Registrant?s Certifying Accountant? of the Company?s Current Report on Form 8-K dated December 2, |
|
| December 3, 2021 |
Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 2, 2021 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 4, 2021 |
Asset Purchase Agreement between Nephros, Inc. and GenArraytion, Inc. dated July 9, 2021. * Exhibit 10.1 ASSET PURCHASE AGREEMENT THIS ASSET PURCHASE AGREEMENT (this ?Agreement?), dated as of July 9, 2021, is among Nephros, Inc., a Delaware corporation (the ?Purchaser?), GenArraytion, Inc., a Delaware corporation (the ?Company?), and R. Paul Schaudies (?Schaudies? or the ?Shareholder?). Capitalized terms used but not otherwise defined have the meanings in Article VII. RECITALS A. The Com |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPH |
|
| October 8, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 8, 2021 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 8, 2021 |
Exhibit 99.1 Nephros Announces Preliminary Results for Third Quarter of 2021 Anticipates Net Revenue of $2.6 Million, a 24% Year-Over-Year Increase SOUTH ORANGE, NJ, October 8, 2021 ? Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced preliminary results for the third quarter |
|
| September 15, 2021 |
NEPHROS, INC. 123,981 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-259370 NEPHROS, INC. 123,981 Shares of Common Stock The selling stockholder identified on page 10 of this prospectus is offering on a resale basis a total of 123,981 shares of our common stock. The selling stockholder may offer such shares from time to time to or through brokers, dealers or other agents, or directly to other purchase |
|
| September 10, 2021 |
Nephros, Inc. 380 Lackawanna Place South Orange, NJ 07079 (201) 343-5202 CORRESP 1 filename1.htm Nephros, Inc. 380 Lackawanna Place South Orange, NJ 07079 (201) 343-5202 September 10, 2021 Via Edgar Transmission Mr. Gary Guttenberg Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Re: Nephros, Inc. (the “Company”) Registration Statement on Form S-3 File No. 333-259370 Dear Mr. Guttenberg: In accordance wit |
|
| September 7, 2021 |
As filed with the Securities and Exchange Commission on September 7, 2021 Registration No. |
|
| September 2, 2021 |
Nephros Appoints Wes Lobo to Chief Commercial Officer EX-99.1 2 ex99-1.htm Exhibit 99.1 Nephros Appoints Wes Lobo to Chief Commercial Officer SOUTH ORANGE, NJ, September 1, 2021 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing innovative filtration and pathogen detection solutions to healthcare and commercial markets, today announced the appointment of Wes Lobo to the role of Chief Commercial Officer. Mr. Lobo first joined |
|
| September 2, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2021 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation) 001-32288 (Commission File Number) 13-39 |
|
| August 5, 2021 |
Exhibit 99.1 Nephros Announces Results for Quarter Ended June 30, 2021 Second Quarter Net Revenue of $2.3 Million; 44% Year-Over-Year Increase; Strategic Acquisition of GenArraytion, Inc.; HDF Product Submitted to FDA for 510(k) Clearance SOUTH ORANGE, NJ, August 5, 2021 ? Nephros, Inc. (Nasdaq: NEPH), a leading biotechnology company providing innovative filtration and pathogen detection solutions |
|
| August 5, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPHROS, |
|
| July 12, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Nephros Announces Acquisition of GenArraytion, Inc. Strategic Acquisition Accelerates Pathogen Detection Product Development SOUTH ORANGE, NJ, July 12, 2021 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced that it has acquired substantiall |
|
| July 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2021 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| July 8, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2021 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation) 001-32288 (Commission File Number) 13-3971809 |
|
| July 8, 2021 |
Exhibit 99.1 Nephros Announces Preliminary Results for Second Quarter of 2021 Anticipates Net Revenue of $2.2 Million, Greater Than 40% Year-Over-Year Increase; Submits HDF Product to FDA for 510(k) Clearance SOUTH ORANGE, NJ, July 8, 2021 ? Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, |
|
| June 11, 2021 |
NEPH / Nephros, Inc. / Evans Daron Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* NEPHROS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 640671400 (CUSIP Number) Daron Evans c/o Nephros, Inc. 380 Lackawanna Place South Orange, NJ 07079 (Name, Address and Telephone Number of Persons Authorized to Receive Notices and |
|
| June 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of 1933 NEPHROS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3971809 (State or Other Jurisdiction of (I.R.S. Employer Incorporation or Organization) Identification Number) 380 Lackawanna Place South Orange, NJ 07079 (Address of Principal Execu |
|
| May 20, 2021 |
UNITES STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2021 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 6, 2021 |
Separation Agreement and Release, between the Company and Daniel DAgostino, dated January 28, 2021.* Exhibit 10.1 January 28, 2021 Dan DAgostino [Omitted] Re: Separation Agreement and Release Dear Dan: As we have discussed with you, your employment with Nephros, Inc. (?Nephros?) will terminate effective today January 28, 2021 and you will be paid in full through the January 31, 2021 pay cycle. While we are not required to do so, we are willing to offer separation pay to assist you with your trans |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 6, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPH |
|
| May 6, 2021 |
Exhibit 99.1 Nephros Announces Results for Quarter Ended March 31, 2021 Net Revenue of $2.7 Million; Highest First Quarter in Company History SOUTH ORANGE, NJ, May 6, 2021 ? Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced results for the three months ended March 31, 2021. F |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P |
|
| April 5, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2021 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 5, 2021 |
Exhibit 99.1 Nephros Announces Preliminary Results for First Quarter of 2021 Anticipates Net Revenue of $2.7 Million; Highest First Quarter in Company History SOUTH ORANGE, NJ, April 5, 2021 ? Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced preliminary results for the first |
|
| March 31, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 26, 2021 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2021 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| March 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32288 NEPHROS, INC. |
|
| March 1, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation) 001-32288 (Commission File Number) 13-397180 |
|
| March 1, 2021 |
EX-10.55 2 ex10-55.htm Exhibit 10.55 November 30, 2020 Wesley S. Lobo [OMITTED] Dear Wes, It gives me great pleasure to offer you the position of Chief Marketing Officer (“CMO”) at Nephros, Inc. ( “Nephros”). As CMO, you will be responsible for developing and executing Nephros’s marketing and revenue growth strategies, which will include product planning, product-market fit, go-to-market, building |
|
| March 1, 2021 |
List of Subsidiaries of Nephros, Inc. * Exhibit 21.1 Subsidiaries of Nephros, Inc. Name Jurisdiction Percentage Equity Nephros International Limited Ireland 100% Biocon 1, LLC Nevada 100% Aether Water Systems, LLC Nevada 100% Specialty Renal Products, Inc. Delaware 62.5% |
|
| March 1, 2021 |
Exhibit 99.1 Nephros Reports 2020 Fourth Quarter and Full Year Financial Results Fourth Quarter Net Revenue $2.3 Million, Up 10% Sequentially Over Third Quarter Full Year Revenue $8.6 million, Down 17% Against Prior Year SOUTH ORANGE, NJ, March 1, 2021 – Nephros, Inc. (Nasdaq:NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commerci |
|
| February 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2021 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Nephros, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 640671400 (CUSIP Number) January 26, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 12, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 12, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Nephros Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020 Anticipates $2.3 Million Revenue in Fourth Quarter, $8.5 Million in Full-Year; Quarterly Revenue Grew 9% Sequentially Over Third Quarter; Full Year Revenue Declined 17% SOUTH ORANGE, NJ, January 12, 2021 – Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company (“Nephros”) tha |
|
| November 5, 2020 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (this “Agreement”), is entered into as of August 23, 2020, and effective as of August 24, 2020 (the “Effective Date”), by and between Nephros, Inc., a Delaware corporation having its executive offices and principal place of business at 380 Lackawanna Place, South Orange, New Jersey 07079 (the “Company”), and Andrew As |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 5, 2020 |
Exhibit 99.1 Nephros Appoints Dan D’Agostino as CFO and Reports Third Quarter Financial Results Finance Veteran Strengthens Management Team; Quarter-over-Quarter Net Revenue up 34%; Year-over-Year down 31% SOUTH ORANGE, NJ, November 5, 2020 – Nephros, Inc. (Nasdaq:NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems t |
|
| November 5, 2020 |
Exhibit 10.3 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”), entered into as of August 26, 2020 and effective as of August 24, 2020 (the “Effective Date”) is by and between Specialty Renal Products, Inc., a Delaware Corporation (“SRP”) and Daron G. Evans (“Consultant”). WHEREAS, SRP desires to engage Consultant as a consultant under the terms and conditions of this Agreement, an |
|
| November 5, 2020 |
Letter Agreement dated September 22, 2020, between Dan D’Agostino and Nephros, Inc. Exhibit 10.1 September 22, 2020 Dan D’Agostino [Address Omitted] Dear Dan, I am very pleased to offer you the position of Chief Financial Officer at Nephros (the “Company”). As CFO, your primary responsibilities will be to manage the financial, risk management, and administrative operations of the company, including accounting, financial reporting, financial strategies, and control systems. You wi |
|
| November 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 |
|
| November 5, 2020 |
Exhibit 10.2 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”), entered into as of August 24, 2020 and effective as of August 24, 2020 (the “Effective Date”) is by and between Nephros, Inc., a Delaware Corporation (“Nephros”) and Daron G. Evans (“Consultant”). WHEREAS, Nephros desires to engage Consultant as a consultant under the terms and conditions of this Agreement, and Consult |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 26, 2020 |
640671400 / Nephros Inc / WEXFORD CAPITAL LP - WEXFORD CAPITAL 13DA11 10-26-2020 Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D A11 Under the Securities Exchange Act of 1934 (Amendment No. 11)* NEPHROS, INC. (Name of Issuer) Shares of Common Stock, par value $0.001 per share (Title of Class of Securities) 640671400 (CUSIP Number) Arthur H. Amron, Esq. Wexford Capital LP 677 Washington Boulevard, Suite 500 Stamford, CT 06901 (203) 862-7012 (Name, Address |
|
| October 21, 2020 |
640671400 / Nephros Inc / PESSIN NORMAN H - SC 13D/A Activist Investment SC 13D/A 1 brhc10016139sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No.2)* Nephros, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 640671400 Cusip Number Norman H. Pessin Sandra F. Pessin Brian L. Pessin 500 Fifth Ave, Suite 2240 New York, NY 10110 |
|
| October 21, 2020 |
NEPH / Nephros, Inc. / Samjo Capital LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 20, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 20, 2020 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 SECOND AMENDMENT TO MEMBERSHIP INTEREST PURCHASE AGREEMENT THIS SECOND AMENDMENT TO MEMBERSHIP INTEREST PURCHASE AGREEMENT (this “Amendment”) is entered into as of October 15, 2020, by and between Nephros, Inc. (the “Purchaser”) and Gregory Lucas (the “Member”). Capitalized terms used but not defined in this Amendment will have the meanings ascribed to them pursua |
|
| October 16, 2020 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 15, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Num |
|
| October 16, 2020 |
Exhibit 10.1 [FORM OF] SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of October 15, 2020, by and among Nephros, Inc., a Delaware corporation (the “Company”), and the purchasers identified on the signature page hereto (including each purchaser’s successors and assigns, individually, a “Purchaser,” and collectively, the “Purchasers”). WHEREAS, subjec |
|
| October 16, 2020 |
Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock Exhibit 99.1 Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock SOUTH ORANGE, NJ, October 16, 2020 – Nephros, Inc. (Nasdaq: NEPH) (“Nephros” or the “Company”), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical device and commercial markets, today announced the pricing of a re |
|
| October 16, 2020 |
NEPHROS, INC. 833,333 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-234528 PROSPECTUS SUPPLEMENT (To Prospectus dated December 6, 2019) NEPHROS, INC. 833,333 Shares of Common Stock We are offering 833,333 shares of common stock, par value $0.001 per share in this offering. Each share of common stock will be sold at a price of $6.00. Our common stock is listed on the Nasdaq Capital Market under the symbol “NEPH. |
|
| October 13, 2020 |
EX-10.2 3 ex10-2.htm Exhibit 10.2 THE OFFER AND SALE OF THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THIS NOTE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED. FURTHER, |
|
| October 13, 2020 |
Exhibit 10.1 LOAN AGREEMENT This LOAN AGREEMENT (this “Agreement”) is made and entered into as of October 7, 2020, by and among Specialty Renal Products, Inc., a Delaware corporation (“Borrower”), and Nephros, Inc., a Delaware corporation (the “Lender”). RECITALS A. Borrower wishes to borrow from the Lender up to $1,258,555.56 for the purposes described in Section 2.1 hereof. B. The Lender desires |
|
| October 13, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| October 6, 2020 |
Nephros Announces Preliminary Third Quarter Revenues of $2.1 Million Exhibit 99.1 Nephros Announces Preliminary Third Quarter Revenues of $2.1 Million SOUTH ORANGE, NJ, October 6, 2020 – Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced preliminary financial results for the quarter ended September 30, 2020 |
|
| October 6, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation) 001-32288 (Commission File Number) 13-3971 |
|
| August 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation) 001-32288 (Commission File Number) 13-3971 |
|
| August 14, 2020 |
Exhibit 99.1 Nephros Names Andy Astor President and Chief Executive Officer Daron Evans to Remain Senior Science Advisor and CEO of Specialty Renal Products SOUTH ORANGE, NJ, August 14, 2020 – Nephros, Inc. (Nasdaq:NEPH), a commercial-stage company that develops and sells water purification products and pathogen detection systems to the medical and commercial markets, today announced that Andy Ast |
|
| August 5, 2020 |
Exhibit 10.3 amended and restated Secured Promissory Note (Single Advance – Non-Revolving) $749,108.15 May 26th, 2020 FOR VALUE RECEIVED, NEPHROS, INC., a Delaware corporation (“Borrower”), promises to pay to TECH CAPITAL, LLC, a California limited liability company (“Lender”), or order, at Lender’s place of business at 2010 North First Street, Suite 300, San Jose, California 95131, or at such oth |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 5, 2020 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 FIRST AMENDMENT TO MEMBERSHIP INTEREST PURCHASE AGREEMENT THIS FIRST AMENDMENT TO MEMBERSHIP INTEREST PURCHASE AGREEMENT (this “Amendment”) is entered into as of June 24, 2020, by and between Nephros, Inc. (“Purchaser”) and Gregory Lucas (the “Member”). Capitalized terms used but not defined in this Amendment will have the meanings ascribed to them pursuant to the |
|
| August 5, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPHR |
|
| August 5, 2020 |
Exhibit 10.2 AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT This Amended and Loan and Security Agreement (as amended hereafter, this “Agreement”) is entered into as of May 26th, 2020 and confirms the understanding and agreement by and between TECH CAPITAL, LLC, a California limited liability company (“Lender”), with its headquarters at 2010 North First Street, Suite 300, San Jose, California 951 |
|
| August 5, 2020 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation) 001-32288 (Commission File |
|
| August 5, 2020 |
Nephros Reports Second Quarter Financial Results Net Revenue down 32% due to COVID-19 Interruptions Exhibit 99.1 Nephros Reports Second Quarter Financial Results Net Revenue down 32% due to COVID-19 Interruptions SOUTH ORANGE, NJ, August 5, 2020 – Nephros, Inc. (Nasdaq:NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced financial results for the three months en |
|
| August 5, 2020 |
EX-10.4 5 ex10-4.htm Exhibit 10.4 U.S. SMALL BUSINESS ADMINISTRATION PAYCHECK PROTECTION PROGRAM NOTE SBA Loan #: [omitted] SBA Loan Name: Paycheck Protection Program Loan Loan Date: 4/22/2020 Loan Amount: $478,700.00 Interest Rate: 1.00% fixed Borrower: Nephros, Inc. Lender: First Republic Bank This Note represents the Loan (as defined below) made by Lender pursuant to the Paycheck Protection Pro |
|
| July 8, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation) 001-32288 (Commission File Number) 13-3971809 |
|
| July 8, 2020 |
Exhibit 99.1 Nephros Announces Preliminary Financial Results for Second Quarter 2020 Anticipates $1.6 Million Net Revenues SOUTH ORANGE, NJ, July 8, 2020 – Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced preliminary financial results fo |
|
| May 22, 2020 |
UNITES STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 21, 2020 |
S-8 1 forms-8.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of 1933 NEPHROS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3971809 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification Number) 380 Lackawanna Place South Orange, NJ 07079 (Address |
|
| May 11, 2020 |
Exhibit 99.1 Nephros, Inc. to Hold Virtual Annual Meeting of Stockholders Executives to Present Business Overviews SOUTH ORANGE, NJ, May 11, 2020 – Nephros, Inc. (Nasdaq: NEPH) announced today that, due to the public health concerns associated with the ongoing coronavirus outbreak and to support the health and well-being of its stockholders, employees, and other partners, the location of the 2020 |
|
| May 11, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 11, 2020 |
DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| May 7, 2020 |
Nephros Reports First Quarter Financial Results Product Revenue up 43% over Q1 2019 Exhibit 99.1 Nephros Reports First Quarter Financial Results Product Revenue up 43% over Q1 2019 SOUTH ORANGE, NJ, May 6, 2020 – Nephros, Inc. (Nasdaq:NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced financial results for the three months ended March 31, 2020. |
|
| May 7, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2020 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-32288 NEPH |
|
| April 10, 2020 |
424B3 1 form424b3.htm Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-234528 PROSPECTUS SUPPLEMENT NO. 2 DATEd April 10, 2020 (To Prospectus Dated December 6, 2019) NEPHROS, INC. This prospectus supplement updates, amends, and supplements the information previously included in the prospectus dated December 6, 2019 relating to the sale or other disposition from time to t |
|
| April 8, 2020 |
640671400 / Nephros Inc / Evans Daron Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* NEPHROS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 640671400 (CUSIP Number) Daron Evans c/o Nephros, Inc. 380 Lackawanna Place South Orange, NJ 07079 (Name, Address and Telephone Number of Persons Authorized to Receive Notices and |
|
| April 8, 2020 |
NEPH / Nephros, Inc. DEFA14A - - DEFA14A 1 formdefa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a |
|
| April 8, 2020 |
NEPH / Nephros, Inc. DEF 14A - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] Definitive P |
|
| April 2, 2020 |
Exhibit 99.1 Nephros Announces Preliminary Financial Results for First Quarter 2020 Anticipates $2.6 Million Net Revenues, Approximately 45% Growth Over 2019 SOUTH ORANGE, NJ, April 2, 2020 – Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announ |
|
| April 2, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Comm |
|
| February 27, 2020 |
NEPH / Nephros, Inc. 10-K - Annual Report - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32288 NEPHROS, INC. |
|
| February 27, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 27, 2020 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Nephros Reports 2019 Fourth Quarter and Full Year Financial Results Fourth Quarter Net Revenue up 96%; Annual Net Revenue up 82% Establishes 2020 Revenue Guidance at $14.5 to $15.5 Million SOUTH ORANGE, NJ, February 27, 2020 – Nephros, Inc. (Nasdaq:NEPH), a commercial stage company that develops and sells high performance water purification products and pathogen d |
|
| February 27, 2020 |
List of Subsidiaries of Nephros, Inc. Exhibit 21.1 Subsidiaries of Nephros, Inc. Name Jurisdiction Percentage Equity Nephros International Limited Ireland 100% Biocon 1, LLC Nevada 100% Aether Water Systems, LLC Nevada 100% Specialty Renal Products, Inc. Delaware 62.5% |
|
| February 27, 2020 |
Exhibit 4.5 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 As of December 31, 2019, Nephros, Inc. (the “Company”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): Common Stock. Description of Common Stock The following description of the Company’s Com |
|
| January 31, 2020 |
EXHIBIT 1.1 937,500 SHARES of Common Stock NEPHROS, INC. UNDERWRITING AGREEMENT January 31, 2020 Craig-Hallum Capital Group LLC As the Representative of the Several underwriters, if any, named in Schedule I hereto 222 South Ninth Street, Suite 350 Minneapolis, Minnesota 55402 Ladies and Gentlemen: The undersigned, Nephros, Inc., a company incorporated under the laws of Delaware (collectively with |
|
| January 31, 2020 |
NEPHROS, INC. 937,500 Shares of Common Stock 424B5 1 form424b5.htm Filed Pursuant to Rule 424(b)(5) Registration No. 333-234528 PROSPECTUS SUPPLEMENT (To Prospectus dated December 6, 2019) NEPHROS, INC. 937,500 Shares of Common Stock We are offering 937,500 shares of common stock, par value $0.001 per share in this offering. The public offering price for each share of common stock is $8.00. Our common stock is listed on the Nasdaq Capital Ma |
|
| January 31, 2020 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (C |
|
| January 31, 2020 |
Nephros Announces Pricing of $7.5 Million Underwritten Offering of Common Stock Nephros Announces Pricing of $7.5 Million Underwritten Offering of Common Stock SOUTH ORANGE, NJ, January 31, 2020 – Nephros, Inc. (Nasdaq: NEPH) (“Nephros” or the “Company”), a a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical device and commercial markets, today announced the pricing of a firm commitment |
|
| January 27, 2020 |
Dear Friends and Shareholders, EX-99.1 2 ex99-1.htm Exhibit 99.1 Dear Friends and Shareholders, With the turn of the new year, we are writing to provide a comprehensive update about Nephros and our plans for the future. In the two years since our last shareholder letter, we have grown revenues over 200%, redesigned our Hemodiafiltration (HDF) Assist Device, purchased Aether Water Systems to pursue large opportunities in the com |
|
| January 27, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Num |
|
| January 9, 2020 |
Nephros Announces Launch of PluraPathTM, a Real-Time, Portable, Water Pathogen Detection System Exhibit 99.1 Nephros Announces Launch of PluraPathTM, a Real-Time, Portable, Water Pathogen Detection System SOUTH ORANGE, NJ, January 9, 2020 – Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical device and commercial markets, today announced that it has formally launched PluraP |
|
| January 9, 2020 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 6, 2020 |
Exhibit 99.1 Nephros Announces Preliminary Financial Results for Fourth Quarter and Fiscal Year 2019 Anticipates $10.3 Million Full-Year Revenue, Approximately 82% Growth Over 2018; Fourth Quarter Year-Over-Year Revenue Growth Approximately 99% SOUTH ORANGE, NJ, January 6, 2020 – Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification pr |
|
| January 6, 2020 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2020 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| December 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 20, 2019 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| December 26, 2019 |
Exhibit 10.1 FIRST MODIFICATION TO LOAN AND SECURITY AGREEMENT This First Modification to Loan and Security Agreement (this “Modification”) is entered into by and between NEPHROS, INC., a Delaware corporation (“Borrower”), on the one hand, and TECH CAPITAL, LLC, a California limited liability company (“Lender”), on the other hand, as of this 20th day of December, 2019 at San Jose, California. RECI |
|
| December 4, 2019 |
NEPH / Nephros, Inc. CORRESP - - Nephros, Inc. 380 Lackawanna Place South Orange, NJ 07079 (201) 343-5202 December 4, 2019 Via Edgar Transmission Ms. Irene Paik Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Re: Nephros, Inc. (the “Company”) Registration Statement on Form S-3 File No. 333-234528 Dear Ms. Paik: On behalf of the Company, the undersigned respectfully |
|
| November 27, 2019 |
NEPH / Nephros, Inc. S-3/A - - S-3/A 1 forms-3a.htm As filed with the Securities and Exchange Commission on November 27, 2019 Registration No. 333-234528 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEPHROS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 13-3971809 (State or Other Jurisdiction of |
|
| November 27, 2019 |
NEPH / Nephros, Inc. CORRESP - - CORRESP 1 filename1.htm November 27, 2019 Via Edgar Transmission Ms. Irene Paik Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D.C. 20549 Re: Nephros, Inc. (the “Company”) Registration Statement on Form S-3 Filed November 6, 2019 File No. 333-234528 Dear Ms. Paik: As counsel for the Company and on its behalf, this letter is being submitted in |
|
| November 6, 2019 |
As filed with the Securities and Exchange Commission on November 6, 2019 Registration No. |
|
| November 6, 2019 |
Exhibit 4.13 NEPHROS, INC. and , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1. DEFINITIONS. 1 1.2. OTHER DEFINITIONS. 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT. 4 1.4. RULES OF CONSTRUCTION. 5 ARTICLE 2 THE SECURITIES 5 2.1. ISSUABLE IN SERIES. 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES. 5 2.3. EXECUT |
|
| November 6, 2019 |
10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission Fil |
|
| November 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2019 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 6, 2019 |
EX-99.1 2 ex99-1.htm Nephros Reports Third Quarter Financial Results Product Revenue up 85% over Q3 2018 Reiterates Full-Year Revenue Guidance of $9.5-10 Million SOUTH ORANGE, NJ, November 6, 2019 – Nephros, Inc. (Nasdaq:NEPH), a commercial stage company that develops and sells high performance water purification products to the medical device and commercial markets, today announced financial resu |
|
| October 16, 2019 |
NEPHROS, INC. 493,827 Shares of Common Stock 424B3 1 form424b3.htm PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-232708 NEPHROS, INC. 493,827 Shares of Common Stock The selling stockholders identified beginning on page 10 of this prospectus are offering on a resale basis a total of 493,827 shares of our common stock. We will not receive any proceeds from the sale of these shares by the selling stockholders. Shares of our c |
|
| October 16, 2019 |
NEPHROS, INC. 1,970,365 Shares of Common Stock 424B3 1 form424b3.htm PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-225109 NEPHROS, INC. 1,970,365 Shares of Common Stock The selling stockholders identified beginning on page 13 of this prospectus are offering on a resale basis a total of 1,970,365 shares of our common stock, of which 588,725 were issued or are issuable upon the exercise of certain warrants. We will not receive |
|
| October 9, 2019 |
NEPH / Nephros, Inc. POS AM - - POS AM 1 posam.htm As filed with the Securities and Exchange Commission on October 9, 2019 Registration No. 333-232708 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEPHROS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 13-3971809 (State o |
|
| October 9, 2019 |
NEPH / Nephros, Inc. POS AM - - POS AM 1 posam.htm As filed with the Securities and Exchange Commission on October 9, 2019 Registration No. 333-225109 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 ON FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 NEPHROS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 13-3971809 (State o |
|
| October 7, 2019 |
Exhibit 99.1 Nephros Announces Preliminary Financial Results for Third Quarter 2019 Anticipates $3.1 Million Product Revenue, 85% Growth Over 2018; Increases Full-Year Revenue Guidance to $9.5-10 Million SOUTH ORANGE, NJ, October 7, 2019 – Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products to the medical device and commerci |
|
| October 7, 2019 |
Results of Operations and Financial Condition, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2019 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Co |
|
| August 13, 2019 |
8-A12B 1 form8a-12b.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 NEPHROS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3971809 (State of incorporation or organization) (I.R.S. Employer Identification No.) 380 |
|
| August 13, 2019 |
Nephros Announces Listing on Nasdaq Capital Market Exhibit 99.1 Nephros Announces Listing on Nasdaq Capital Market SOUTH ORANGE, NJ, August 13, 2019 – Nephros, Inc. (OTCQB: NEPH), a commercial-stage company that develops and sells high performance water purification products to the medical device and commercial markets, today announced that its common shares have been approved to list on the Nasdaq Capital Market (“Nasdaq”). “I am grateful to the |
|
| August 13, 2019 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2019 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 8, 2019 |
424B3 1 form424b3.htm Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-232708 PROSPECTUS SUPPLEMENT NO. 1 DATEd AUGUST 7, 2019 (To Prospectus Dated July 31, 2019) NEPHROS, INC. This is a supplement (“Prospectus Supplement No. 1”) to our prospectus, dated July 31, 2019 (the “Prospectus”), relating to up to 493,827 shares of our common stock. This Prospectus Supplement No. |
|
| August 8, 2019 |
424B3 1 form424b3.htm Prospectus Supplement Filed Pursuant to Rule 424(b)(3) Registration No. 333-225109 PROSPECTUS SUPPLEMENT NO. 1 DATEd AUGUST 7, 2019 (To Prospectus Dated May 13, 2019) NEPHROS, INC. This is a supplement (“Prospectus Supplement No. 1”) to our prospectus, dated May 13, 2019 (the “Prospectus”), relating to up to 1,970,367 shares of our common stock, of which 588,705 were issued o |
|
| August 7, 2019 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2019 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware 001-32288 13-3971809 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 7, 2019 |
Exhibit 99.1 Nephros Reports Second Quarter Financial Results Product Revenue up 88% over Q2 2018; Reiterates 2019 Full-Year Revenue Guidance SOUTH ORANGE, NJ, August 7, 2019 – Nephros, Inc. (OTCQB:NEPH), a commercial stage company that develops and sells high performance water purification products to the medical device and commercial markets, today announced financial results for the three month |
|
| August 7, 2019 |
10-Q 1 form10-q.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2019 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Num |
|
| August 7, 2019 |
EXHIBIT 3.1 CERTIFICATE OF AMENDMENT OF THE FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEPHROS, INC. Pursuant to Section 242 of the General Corporation Law of the State of Delaware It is hereby certified that: FIRST: The original Certificate of Incorporation of Nephros, Inc. was filed with the Secretary of State of the State of Delaware on April 3, 1997, and was amended and restat |
|
| August 2, 2019 |
Nephros Announces Second Quarter 2019 Financial Results Conference Call and Record Revenue of Over $1 Million in July SOUTH ORANGE, NJ, July 30, 2019 – Nephros, Inc. |
|
| August 2, 2019 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITES STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2019 NEPHROS, INC. (Exact name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation) 001-32288 (Commission File Number) 13-397180 |
|
| July 31, 2019 |
NEPHROS, INC. 493,827 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) File No: 333-225109 PROSPECTUS NEPHROS, INC. 493,827 Shares of Common Stock The selling stockholders identified beginning on page 21 of this prospectus are offering on a resale basis a total of 493,827 shares of our common stock. We will not receive any proceeds from the sale of these shares by the selling stockholders. Shares of our common stock are quoted on the |
|
| July 29, 2019 |
NEPH / Nephros, Inc. CORRESP - - Nephros, Inc. 380 Lackawanna Place South Orange, New Jersey 07079 (201) 343-5202 July 29, 2019 VIA EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Ms. Heather Percival Re: Nephros, Inc. (the “Company”) Registration Statement on Form S-1 File No. 333-232708 Dear Ms. Percival: On behalf of the Company, the undersigned respectfully requests that the |
